|
US10155038B2
(en)
|
2007-02-02 |
2018-12-18 |
Yale University |
Cells prepared by transient transfection and methods of use thereof
|
|
US9249423B2
(en)
|
2007-02-02 |
2016-02-02 |
Yale University |
Method of de-differentiating and re-differentiating somatic cells using RNA
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP2859093A4
(en)
*
|
2012-06-11 |
2016-08-17 |
Wolf Wilson Mfg Corp |
IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES
|
|
CN104619334A
(zh)
|
2012-08-09 |
2015-05-13 |
利兰斯坦福初级大学董事会 |
超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
CN113005091A
(zh)
*
|
2013-02-06 |
2021-06-22 |
细胞基因公司 |
具有改进特异性的修饰的t淋巴细胞
|
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
|
JP6647868B2
(ja)
|
2013-02-20 |
2020-02-14 |
ノバルティス アーゲー |
ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置
|
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
JP6493692B2
(ja)
|
2013-03-15 |
2019-04-10 |
セルジーン コーポレイション |
修飾されたｔリンパ球
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
US10584158B2
(en)
|
2013-04-17 |
2020-03-10 |
Baylor College Of Medicine |
Immunosuppressive TGF-β signal converter
|
|
EP3008092A4
(en)
*
|
2013-06-14 |
2017-01-11 |
The University Of Houston System |
Targeting tumor neovasculature with modified chimeric antigen receptors
|
|
WO2015010096A1
(en)
*
|
2013-07-18 |
2015-01-22 |
Baylor College Of Medicine |
Method of enhancing potency of immune cells
|
|
EP3049526B1
(en)
|
2013-09-24 |
2021-02-24 |
Medicenna Therapeutics, Inc. |
Interleukin-4 receptor-binding fusion proteins and uses thereof
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
WO2015112626A1
(en)
|
2014-01-21 |
2015-07-30 |
June Carl H |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
AU2015244039B2
(en)
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
CA2945388A1
(en)
*
|
2014-04-23 |
2015-10-29 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) for use in therapy and methods for making the same
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用ｃｄ３３嵌合抗原受體治療癌症
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
SG10201913782UA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cll-1 chimeric antigen receptor
|
|
JP6631865B2
(ja)
*
|
2014-08-11 |
2020-01-15 |
日本化薬株式会社 |
ＴＧＦβ阻害機能を持つキメラタンパク質
|
|
MX2017002205A
(es)
|
2014-08-19 |
2017-08-21 |
Novartis Ag |
Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
|
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
KR20170068504A
(ko)
|
2014-10-08 |
2017-06-19 |
노파르티스 아게 |
키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
|
|
MA41538A
(fr)
*
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
|
RU2021118125A
(ru)
|
2014-12-29 |
2022-04-06 |
Новартис Аг |
Способы получения экспрессирующих химерный антигенный рецептор клеток
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
US10828353B2
(en)
|
2015-01-31 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for T cell delivery of therapeutic molecules
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
WO2016170541A1
(en)
|
2015-04-21 |
2016-10-27 |
Enlivex Therapeutics Ltd. |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
|
EP3865139B1
(en)
|
2015-02-18 |
2023-05-03 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
EP4406604A3
(en)
|
2015-03-05 |
2024-10-23 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
|
US20180072990A1
(en)
*
|
2015-03-20 |
2018-03-15 |
Children's National Medical Center |
Generating virus or other antigen-specific t cells from a naïve t cell population
|
|
JP6961490B2
(ja)
|
2015-04-08 |
2021-11-05 |
ノバルティス アーゲー |
Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
|
|
AU2016249005B2
(en)
|
2015-04-17 |
2022-06-16 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CN104910279B
(zh)
*
|
2015-06-05 |
2019-02-22 |
重庆精准生物技术有限公司 |
靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用
|
|
CA2992551A1
(en)
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
GB201514875D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Receptor
|
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
GB201518816D0
(en)
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Receptor
|
|
WO2017093969A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
EP4643874A3
(en)
|
2015-12-22 |
2026-02-11 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
CN109069539A
(zh)
|
2016-02-18 |
2018-12-21 |
恩立夫克治疗有限责任公司 |
用于癌症治疗的联合免疫疗法和细胞因子控制疗法
|
|
US12590321B2
(en)
|
2016-03-19 |
2026-03-31 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
|
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
CU24649B1
(es)
*
|
2016-03-19 |
2023-02-13 |
Exuma Biotech Corp |
Retrovirus recombinantes incompetentes de replicación para la transducción de linfocitos y expansión regulada de los mismos
|
|
US11325948B2
(en)
|
2016-03-19 |
2022-05-10 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
KR20230167769A
(ko)
*
|
2016-08-26 |
2023-12-11 |
베이롤 칼리지 오브 메드신 |
세포 치료요법을 위한 항상성 활성 사이토킨 수용체
|
|
BR112019006781A2
(pt)
|
2016-10-07 |
2019-07-30 |
Novartis Ag |
receptores de antígeno quiméricos para o tratamento de câncer
|
|
JP7100028B2
(ja)
|
2016-10-20 |
2022-07-12 |
セルジーン コーポレイション |
セレブロン系のヘテロ二量体化可能なキメラ抗原受容体
|
|
MA46862A
(fr)
|
2016-11-17 |
2019-09-25 |
Bluebird Bio Inc |
Convertisseur de signaux tgf béta
|
|
ES2912408T3
(es)
|
2017-01-26 |
2022-05-25 |
Novartis Ag |
Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
|
|
GB201702617D0
(en)
*
|
2017-02-17 |
2017-04-05 |
Autolus Ltd |
Receptor
|
|
KR102879522B1
(ko)
*
|
2017-03-03 |
2025-11-04 |
엑수마 바이오테크, 코포레이션 |
림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물
|
|
CN119409836A
(zh)
|
2017-03-17 |
2025-02-11 |
弗雷德哈钦森癌症中心 |
免疫调节融合蛋白及其用途
|
|
WO2018175636A2
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
WO2018191619A1
(en)
|
2017-04-13 |
2018-10-18 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
EP3694558B1
(en)
|
2017-10-10 |
2024-04-10 |
Medicenna Therapeutics Inc. |
Il-4-fusion formulations for treatment of central nervous system (cns) tumors
|
|
AU2018351050B2
(en)
|
2017-10-18 |
2025-09-18 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
CN118420783A
(zh)
*
|
2017-12-06 |
2024-08-02 |
恺兴生命科技(上海)有限公司 |
嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用
|
|
US12539308B2
(en)
|
2018-01-08 |
2026-02-03 |
The Trustees Of The University Of Pennsylvania |
Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
|
|
CN111819192A
(zh)
*
|
2018-03-02 |
2020-10-23 |
艾洛基治疗公司 |
可诱导的嵌合细胞激素受体
|
|
MX2020009272A
(es)
|
2018-03-06 |
2021-01-08 |
Univ Pennsylvania |
Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
|
|
WO2019239213A2
(en)
|
2018-06-01 |
2019-12-19 |
Medicenna Therapeutics Inc. |
Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
|
|
US12590133B2
(en)
*
|
2018-06-01 |
2026-03-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
TWI890660B
(zh)
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
CN110615843B
(zh)
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种包含第三信号受体的嵌合抗原受体及其应用
|
|
AU2019359890B2
(en)
|
2018-10-17 |
2024-10-24 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
US11419898B2
(en)
|
2018-10-17 |
2022-08-23 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
US20200147137A1
(en)
*
|
2018-11-08 |
2020-05-14 |
WUGEN, Inc. |
Compositions and methods for treatment of cancer
|
|
CN109735558B
(zh)
*
|
2018-12-12 |
2022-04-15 |
中南大学 |
一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
|
|
PE20211902A1
(es)
*
|
2019-03-01 |
2021-09-27 |
Allogene Therapeutics Inc |
Receptores de citocinas quimericos constitutivamente activos
|
|
AU2020232216B2
(en)
*
|
2019-03-01 |
2025-09-25 |
Allogene Therapeutics, Inc. |
Chimeric cytokine receptors bearing a PD-1 ectodomain
|
|
CA3139011A1
(en)
|
2019-05-08 |
2020-11-12 |
Medigene Immunotherapies Gmbh |
Engineered t cells
|
|
US12528856B2
(en)
|
2019-08-30 |
2026-01-20 |
Allogene Therapeutics, Inc. |
Chimeric cytokine receptors comprising TGF β binding domains
|
|
WO2021042060A1
(en)
|
2019-08-30 |
2021-03-04 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
|
KR102275668B1
(ko)
*
|
2019-09-26 |
2021-07-12 |
충북대학교 산학협력단 |
면역신호의 변환이 가능한 키메릭 사이토카인 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
|
|
EP4065157A1
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
MX2022010340A
(es)
|
2020-02-24 |
2022-09-19 |
Allogene Therapeutics Inc |
Celulas t con car de bcma con actividades mejoradas.
|
|
CN115427440A
(zh)
|
2020-02-25 |
2022-12-02 |
圭尔医疗有限公司 |
用于工程化细胞的嵌合受体
|
|
CN116529266A
(zh)
|
2020-08-31 |
2023-08-01 |
耶鲁大学 |
用于将核酸递送到细胞的组合物和方法
|
|
EP4402160A4
(en)
*
|
2021-09-17 |
2025-11-19 |
Univ Pennsylvania |
CHIMERIC ANTIGENIC RECEPTORS COMPRISING AN INTERLEUKIN-9 RECEPTOR SIGNALING DOMAIN
|
|
CA3255500A1
(en)
|
2022-04-08 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
MULTI-PART RECEIVERS AND SIGNALING COMPLEXES
|
|
JP2025540052A
(ja)
|
2022-12-01 |
2025-12-11 |
イェール ユニバーシティー |
細胞内ペイロード送達用刺激応答性トレースレス操作プラットフォーム
|
|
CN120225568A
(zh)
*
|
2022-12-27 |
2025-06-27 |
广州瑞风生物科技有限公司 |
一种融合蛋白及其应用
|
|
EP4403580A1
(en)
|
2023-01-23 |
2024-07-24 |
Medizinische Hochschule Hannover |
Anti-entpd3 chimeric antigen receptor
|
|
CN120981484A
(zh)
|
2023-01-23 |
2025-11-18 |
汉诺威医学院 |
抗entpd3嵌合抗原受体
|
|
AU2024219048A1
(en)
|
2023-02-07 |
2025-08-07 |
Quell Therapeutics Limited |
Culture method for treg cells
|
|
WO2024175805A1
(en)
|
2023-02-24 |
2024-08-29 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
EP4420676A1
(en)
|
2023-02-24 |
2024-08-28 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
CN116284449B
(zh)
*
|
2023-02-27 |
2024-11-19 |
深圳市先康达生命科学有限公司 |
增强型TGF-βR嵌合受体及其应用
|
|
IL322949A
(en)
|
2023-03-03 |
2025-10-01 |
Arsenal Biosciences Inc |
Systems targeting PSMA and CA9
|
|
EP4680728A1
(en)
|
2023-03-17 |
2026-01-21 |
Quell Therapeutics Limited |
Treg therapy
|
|
WO2024194355A1
(en)
|
2023-03-20 |
2024-09-26 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
EP4434539A1
(en)
|
2023-03-20 |
2024-09-25 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
WO2024193687A1
(en)
*
|
2023-03-23 |
2024-09-26 |
Nanjing Legend Biotech Co., Ltd. |
Inverted cytokine receptors and methods of use thereof
|
|
AU2024243972A1
(en)
*
|
2023-04-06 |
2025-10-23 |
Memorial Hospital For Cancer And Allied Diseases |
Il-10 receptor antibodies and methods of use thereof
|
|
CN116496417B
(zh)
*
|
2023-06-27 |
2023-10-10 |
北京市肿瘤防治研究所 |
含有膜型il7的融合蛋白及t细胞
|
|
WO2025016399A1
(en)
*
|
2023-07-17 |
2025-01-23 |
Nanjing Legend Biotech Co., Ltd. |
Fusion proteins and methods of use thereof
|
|
WO2026008994A1
(en)
|
2024-07-04 |
2026-01-08 |
Quell Therapeutics Limited |
Expression construct
|
|
GB202411558D0
(en)
|
2024-08-06 |
2024-09-18 |
Quell Therapeutics Ltd |
Culture method
|